Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
Caplin Point Laboratories's net profit margin of 26.6% in FY2025 reflects excellent profitability, with operating margin at 33.3% and gross margin at 62.1%.
In FY 2025, Caplin Point Laboratories posted a gross margin of 62.1%, an operating margin of 33.3%, a net margin of 26.6%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Caplin Point Laboratories's revenue grew 15.5% to 20.34B and net profit grew 17.3% to 5.41B YoY in FY2025, indicating healthy business momentum.
In FY 2025, Caplin Point Laboratories's revenue grew by 15.5% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Caplin Point Laboratories's ROE of 18.7% in FY2025 indicates good shareholder returns.
In FY 2025, Caplin Point Laboratories reported an ROE of 18.7%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Caplin Point Laboratories's FCF/NI ratio of 0.45x in FY2025 indicates FCF trailing profits — heavy capex or working capital needs may be a factor.
In FY 2025, Caplin Point Laboratories's free cash flow trailed net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Caplin Point Laboratories's OCF/NI ratio of 0.80x in FY2025 indicates reasonable cash conversion from operations.
In FY 2025, Caplin Point Laboratories's operating cash flow trailed net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Caplin Point Laboratories's current ratio of 6.97x in FY2025 indicates excessively high liquidity that may signal inefficient asset management.
In FY 2025, Caplin Point Laboratories reported a current ratio of 6.97. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Caplin Point Laboratories's interest coverage ratio of 1,110.5x in FY2025 indicates comfortable debt servicing capacity.
In FY 2025, Caplin Point Laboratories reported an interest coverage ratio of 1,110.5x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Caplin Point Laboratories's debt-to-equity ratio of 0.00x in FY2025 reflects a conservative, low-leverage capital structure.
In FY 2025, Caplin Point Laboratories reported a debt-to-equity ratio of 0.00. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Caplin Point Laboratories's debt increased 154.8% YoY in FY2025 — rising leverage demands close monitoring.
In FY 2025, Caplin Point Laboratories's total debt increased by 154.8% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Caplin Point Laboratories's diluted shares remained virtually unchanged in FY2025.
Over 2 years (FY2024–FY2025), diluted shares remained essentially unchanged at 76.35M.
In FY 2025, Caplin Point Laboratories's diluted shares increased by 0.0% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025